+
AstraZeneca India To Sell 64-Acre Bengaluru Facility
Real Estate

AstraZeneca India To Sell 64-Acre Bengaluru Facility

AstraZeneca India is set to divest its 64-acre production facility in North Bengaluru as part of a global reassessment of its manufacturing and supply chain operations. This initiative aligns with the parent company’s broader strategy to optimise resources through corporate land monetization. 

According to the reports in the media, the proposed transaction is estimated to bring in over Rs 32 billion. AstraZeneca has reportedly engaged global property consultants to identify potential buyers for the land, which is valued at more than Rs 500 million per acre. Despite previous attempts to sell, the high valuation had posed challenges in securing a deal. 

The company intends to transfer the facility as a fully operational unit and is actively searching for a buyer who can also serve as a contract manufacturing organization (CMO) to continue its existing production and packaging operations, subject to necessary approvals. 

A key part of AstraZeneca Pharma’s global network, the Bengaluru facility is one of nine sites dedicated to clinical trial design and execution. The planned sale underscores AstraZeneca’s broader strategic shift to streamline global operations while maintaining critical pharmaceutical production through external partnerships. 

AstraZeneca India is set to divest its 64-acre production facility in North Bengaluru as part of a global reassessment of its manufacturing and supply chain operations. This initiative aligns with the parent company’s broader strategy to optimise resources through corporate land monetization. According to the reports in the media, the proposed transaction is estimated to bring in over Rs 32 billion. AstraZeneca has reportedly engaged global property consultants to identify potential buyers for the land, which is valued at more than Rs 500 million per acre. Despite previous attempts to sell, the high valuation had posed challenges in securing a deal. The company intends to transfer the facility as a fully operational unit and is actively searching for a buyer who can also serve as a contract manufacturing organization (CMO) to continue its existing production and packaging operations, subject to necessary approvals. A key part of AstraZeneca Pharma’s global network, the Bengaluru facility is one of nine sites dedicated to clinical trial design and execution. The planned sale underscores AstraZeneca’s broader strategic shift to streamline global operations while maintaining critical pharmaceutical production through external partnerships. 

Related Stories

Gold Stories

Next Story
Infrastructure Transport

Mumbai-Ahmedabad Bullet Train’s Surat-Vapi Section Set for 2027

The first section of the Mumbai-Ahmedabad Bullet Train corridor, linking Surat and Vapi, is targeted to begin services in 2027. Construction is expected to be completed by December 2026, while Railway Minister Ashwini Vaishnaw has indicated that an inauguration could take place around the middle of 2027. The National High Speed Rail Corporation (NHSRCL) said the train being manufactured in India is expected to reach the tracks around April or May 2027. The train will undergo extensive testing before the section is opened for passenger services. The project began construction in 2021 and includ..

Next Story
Infrastructure Transport

Indian Railways Approves Four Projects Worth Rs. 7.36 bn Across Four States

Indian Railways has approved four projects with a combined value of Rs. 7.36 bn across Uttar Pradesh, Maharashtra, Andhra Pradesh and Gujarat. The programme covers train protection, signalling, electric traction supply and a road overbridge, with each project assigned to a different railway zone. In Uttar Pradesh, Rs. 2.52 bn has been approved to extend the Kavach 4.0 automatic train protection system across 607.7 km in the Lucknow Division of North Eastern Railway. The system monitors train movements and can apply the brakes if a driver fails to observe a signal or exceeds a safe speed. The w..

Next Story
Infrastructure Urban

Chandru Raheja Sells 1.49% Stake in Mindspace REIT for Rs. 5 bn

Billionaire Chandru Lachmandas Raheja has sold a 1.49 per cent holding in Mindspace Business Parks REIT for Rs. 5 bn through a bulk deal on the BSE. The transaction involved 9.9 mn units and was executed at an average price of Rs. 505 per unit, according to exchange data. Following the sale, units of Mindspace Business Parks REIT were trading 0.18 per cent lower at Rs. 504.05 on Tuesday. Exchange data did not identify the buyers involved in the transaction. Raheja is the chairman of real estate company K Raheja Corp. The sale involved 99,00,990 units, representing 1.49 per cent of the Mumbai-b..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code